Our Mission
At Aztron Medtech, we envision a world where Achilles tendon injuries no longer limit movement or performance. Our mission is to redefine recovery through advanced, minimally invasive repair technologies that set a new global standard for tendon restoration: safer, faster, and more precise.
Join us as we drive the next evolution in sports medicine, combining precision engineering with human-centered design to deliver better outcomes and restore the freedom to move without compromise.
Our Advisors
Partner with renowned surgeons and leading experts to develop cutting-edge solutions for orthopedic soft tissue repair.
Our Milestones
2024
2023
2022
2025
2021
Rebranded as Aztron Medtech
FSS/ ECAT/ GSA Approval
FDA Listed
National Innovation Award, Taiwan
Seed Round Completed
Medtech Innovator APAC
MassChallenge 2022 B2MC Cohort
SelectUSA Medtech World Championship
UC Berkeley SPH Program
FITI National Winner
SNQ Award
Aztron Medtech is advancing minimally invasive tendon repair through surgeon-driven innovation and global collaboration. From early validation in Taiwan to establishing clinical and commercial presence in the United States, every milestone represents our commitment to advancing precision and efficiency in soft tissue repair.
In the United States
Our journey began with strong academic collaboration through the UC Berkeley School of Public Health, supporting our mission to bridge medical innovation and clinical need. In 2022, Aztron (then Astron MedTech) was named Top Winner of the SelectUSA Medtech Investment Summit, standing out among 16 international finalists. By 2025, we achieved FDA listing and FSS / ECAT / GSA approval, expanding access for healthcare providers across the U.S.
In Taiwan
Aztron’s technology was first implemented through a close collaboration with Tzu Chi Hospital. Our innovation was recognized with the Symbol of National Quality (SNQ) Award in 2021 and the National Innovation Award in 2024, affirming both our clinical value and technological impact.